Altasciences Continues to Expand North American Bioanalytical Footprint

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions Saved Articles My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Altasciences Continues to Expand North American Bioanalytical FootprintAuthor of the article: You can save this article by registering for free here. Or sign-in if you have an account.LAVAL, Québec — Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountThe expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027.These investments significantly increase Altasciences’ ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againDesigned to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studies and higher sample volumes while incorporating state-of-the-art instrumentation and advanced laboratory automation for pharmacokinetic and pharmacodynamic assay method development, validation, and sample analysis across the clinical phases of drug development. The additional capacity and streamlined workflows will reduce turnaround times, enabling sponsors to obtain critical bioanalytical data faster, make informed development decisions sooner, and keep clinical programs moving forward.“Our clients are bringing increasingly complex molecules into development, and that is driving unprecedented demand for sophisticated bioanalytical support,” said Lynne Le Sauteur, Vice President, Laboratory Sciences, Altasciences. “We’re investing ahead of that demand by expanding capacity where sponsors need it most and deploying state-of-the-art instrumentation and automation that enhances speed without compromising quality.”The expansion project strengthens Altasciences’ broader North American bioanalytical network, which includes established laboratories in Greater Montréal (Quebec), Seattle (Washington), and Columbia (Missouri). Together, these locations provide sponsors with bioanalytical expertise and capacity across the drug development continuum, supporting programs from nonclinical research through late-stage clinical development while helping de-risk global trials through built-in flexibility, scalability, and business continuity.“Because every Altasciences laboratory is built on the same harmonized scientific platform, sponsors gain the flexibility to scale programs across locations while receiving the consistent, high-quality data they rely on to make critical development decisions,” stated Lynne Le Sauteur.All Altasciences laboratories are designed and built from the ground up using the same validated quality systems, scientific workflows, instrumentation platforms, and operational processes. This network-wide harmonization enables sponsors to leverage capacity across locations, transition work seamlessly between laboratories, and maintain complete confidence in the integrity and consistency of their bioanalytical data.“This investment is about far more than expanding laboratory space,” said Robert Sabelli, Co-Chief Operating Officer, Altasciences. “We’re building one of the industry’s most integrated and scalable bioanalytical networks. As clinical programs become larger, more complex, and increasingly global, sponsors need a partner that can rapidly scale capacity while delivering consistent scientific excellence across every location. That’s exactly what we’re delivering.”These investments reinforce Altasciences’ integrated drug development platform and underscore the company’s commitment to investing in people, facilities, technologies, automation, and the scientific expertise needed to help clients accelerate drug development with confidence.is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across. Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept—helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence. To learn more about Altasciences, visitView source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.